Last reviewed · How we verify
NCT04809350: FAT
Human Milk Fortification With Adjustable Versus Targeted Method
NA trial testing Adjustable Human Milk Fortification in Growth Failure in 52 participants. Status unknown.
31 May 2024
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 52 |
| Start date | 10 November 2023 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Adjustable Human Milk Fortification
- Targeted Human Milk Fortification
Conditions studied
- Growth Failure — all drugs for Growth Failure →
Sponsor
University of Calgary
Who can join
Eligibility, any sex, with Growth Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Research question: Do preterm infants born \<1250 g achieve better weight gain with targeted fortification compared with the adjustable fortification of human milk? Hypothesis: Targeted fortification of human milk results in better weight gain in infants with birth weight \<1250 gr when compared to the adjustable fortification. Study design: Open-label, pragmatic, parallel randomized controlled trial in appropriate for gestational age infants with birth weight \<1250 g.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04809350
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Growth Failure
Currently open trials in the same condition.
- NCT04640805 — Targeted Fortification of Pasteurized Donor Human Milk · NA · active not recruiting
- NCT04325308 — Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk · NA · active not recruiting
- NCT03761498 — Is There a Microbiome Associated With Poor Growth in Preterm Infants? · active not recruiting
- NCT03717584 — A Cohort Study of the Intestinal Microbiota of Premature Infants · active not recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04809350 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 30 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809350.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing